# Detection of human papillomavirus (HPV)-specific T cell response in women with low-grade cervical intraepithelial lesion and HPV vaccinated subjects

## TL;DR

This study develops a test to detect HPV-specific T-cell responses in vaccinated women and those with cervical lesions, finding that T-cell responses are common even in non-target HPV infections.

## Contribution

The study introduces a novel LPR assay for detecting HPV-specific T-cell responses and reveals cross-reactivity among HPV genotypes.

## Key findings

- The LPR assay showed higher sensitivity than the AIM assay for detecting HPV-specific T-cell responses.
- CD4+ T-cell responses were more prevalent than CD8+ responses and were primarily directed against HPV L1 proteins.
- CIN1 patients infected with non-16/18 HPV strains still showed T-cell responses to HPV-16 and -18 L1 proteins, suggesting cross-reactivity.

## Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and HPV-driven cervical cancers remain a major health concern. This study aimed primarily to develop a test for assessing and characterizing HPV-specific T-cell responses, in HPV-vaccinated women and women with cervical intraepithelial neoplasia (CIN)1.

T-cell responses against HPV-16 and 18 L1, E6, and E7 proteins were evaluated by flow cytometry with a 24h activation-induced marker (AIM) and a 7-day lymphoproliferation (LPR) assays in 18 vaccinated and 60 CIN1 women. HPV genotyping was performed on vaginal swab samples.

LPR assay demonstrated higher sensitivity than AIM. T-cell response was mainly directed against L1 and was higher in CD4+ than CD8+ T cells. All vaccinated women exhibited CD4+ T-cell responses against HPV-16 and to a lesser extent HPV-18 L1. Among CIN1 patients, 46.6% and 33.3% showed HPV-16 and -18 L1-specific CD4+ responses, respectively, even when infected with other HPV strains. Responses were predominantly associated with TH1 and TH17 phenotypes.

The LPR assay is a sensitive tool for detecting HPV-specific T-cell responses. The presence of T-cell responses in CIN1 patients infected with non-16/18 HPVs suggests potential cross-reactivity among HPV genotypes.